Founded in Columbia, United States, Senex Biotechnology is dedicated to discovering and developing therapeutic agents aimed at treating cancer, viral diseases, and age-related conditions. The company's core mission is to make cancers curable by targeting proteins that regulate gene expression, which are essential for cancer cells to adapt to adverse conditions, thereby overcoming drug resistance and metastasis. Senex's primary focus is on developing Mediator Kinase Inhibitors and other cancer-targeting therapies.

Senex Biotechnology has garnered attention through its innovative approach and significant progress in the field of cancer therapeutics. The company has been supported by notable investors and has formed strategic partnerships with leading research institutions. Key achievements include the development of promising drug candidates that have shown efficacy in preclinical studies. Senex's impact lies in its potential to revolutionize cancer treatment by addressing drug resistance, offering hope for more effective and durable cancer therapies.